http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2454741-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938b2f1aee88ef5a23e15ff1c0e5bf56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45ca2d27c1000fe6d716028f154b34ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_841e4e826163b21ab231880326d32c55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ca4e2a4a4cbe3cc441c2af4dc664f8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 |
| filingDate | 2008-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ab5e2b30540235c1e12cf058513391e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebd2f267ab25d29696c9aaeceb646b55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6be370e4bcad2941ec9ceed0cf2c579f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b251a351300d5abb8b530961d6ec8f43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_347a2422283dd22b5e615e0655364499 |
| publicationDate | 2014-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2454741-T3 |
| titleOfInvention | Pharmaceutical compositions and methods for treating erectile dysfunction |
| abstract | A pharmaceutical composition in a dosage form suitable for use in the treatment of erectile dysfunction, said composition comprising: (a) Angiotensin- (1-7) and / or an angiotensin receptor agonist- (1-7) and / or an Angiotensin analogue (1-7), wherein the receptor agonist or Angiotensin analogue (1-7) is selected from the group consisting of DAla 7-Ang- (1-7), D-Pro7-Ang- (1-7), and AVE 0991, in an effective amount; and (b) a pharmaceutically acceptable carrier; wherein the composition further comprises at least one anti-hypertensive agent or a PDE inhibitor, wherein at least one anti-hypertensive agent is selected from the group consisting of Angiotensin II receptor antagonists, ACE inhibitors, b-blocking agents and diuretic agents, wherein the Angiotensin II receptor antagonist, is selected from the group consisting of losartan, candersartan, irbersartan, valsartan, olmesartan, eprosartan and telmisartan; the ACE inhibitor is selected from the group consisting of captopril, enalapril, fosinopril, delapril, benzepril; the b-blocking agent is selected from the group consisting of acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metropolol, propanolol, timolol, pindolol, penbutolol, labetalol, carvedilol; The diuretic agent is selected from the group consisting of chlorothiazide, chlorthalidone, furosemide, hydrochlorothiazide, mannitol, metolazone, mixture of amiloride and hydrochlorothiazide, mixture of triamterene and hydrochlorothiazide, and potassium-sparing diuretics, such as amiloride, trirolactone; and wherein the PDE inhibitor is selected from the group consisting of papaverine, sildenafil, vardenafil, tadalafil. |
| priorityDate | 2007-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 414.